BIODELIVERY SCIENCES INTERNATIONAL INC
DelistedCIK 1103021fmd_1KPQBX9C064EAJPZ8V2EJ9DS9XManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Dec 31, 2021, 48 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 55 | 11 | 39 | 48 | 16 | 62 | 56 | 111 | 156 | 167 |
| Cost of revenue | 2 | 2 | 5 | 8 | 11 | 19 | 16 | 22 | 25 | 23 |
| Net interest income | 0 | (1) | (2) | – | – | – | (10) | (19) | (7) | (7) |
| Gross profit | 53 | 9 | 34 | 40 | 4 | 42 | 40 | 90 | 132 | 143 |
| Research and development | 35 | 53 | 34 | 21 | 19 | 13 | 5 | 0 | 0 | – |
| Selling, general and administrative | 10 | 12 | 38 | – | – | – | – | – | – | – |
| Total operating expenses | 46 | 66 | 73 | 75 | 68 | 72 | 64 | 86 | 99 | 106 |
| Operating income | 7 | (56) | (39) | (35) | (64) | (29) | (24) | 4 | 33 | 37 |
| Interest expense | – | 1 | 2 | 3 | 3 | 9 | 10 | 19 | – | – |
| Other non-operating income (expense) | (5) | (1) | (15) | 0 | 0 | (0) | (0) | 0 | (0) | (0) |
| Income before taxes | 2 | (57) | (54) | (38) | (67) | (11) | (34) | (15) | 26 | 30 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | (16) | 0 | 0 | 0 | (55) |
| Net income from continuing operations | 2 | (57) | (54) | (38) | (67) | 5 | (34) | (15) | 26 | 85 |
| Net income | 2 | (57) | (54) | (38) | (67) | 5 | (34) | (15) | 26 | 85 |
| Net income to common shareholders | 2 | (57) | (54) | (38) | (67) | 5 | (46) | (15) | 26 | 85 |